Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-333363      Publish Date : Saturday, January 18, 2014 Visit : 2417

Intl. Congress form | International Congress Report | International Congress Report For Faculty | European Association for clinical Pharmacology and Therapeutics

European Association for clinical Pharmacology and Therapeutics
The Report of European Association for clinical Pharmacology and Therapeutics by Dr.Azam Bakhtiarian
Application Code :
306-0213-0068
 
Created Date : Saturday, November 16, 2013Update Date : Saturday, January 11, 2014IP Address :194.225.51.101
Submit Date : Saturday, January 11, 2014Email : Bakhtiar@sina.tums.ac.ir
Personal Information
Name : Azam
Surname : Bakhtiarian
School/Research center : School of Medicine
If you choose other, please name your Research center :  
Possition : Associate professor
Tel : +98-21-64053215
E-mail : bakhtiar@sina.tums.ac.ir
Information of Congress
Title of the Congress : European Association for clinical Pharmacology and Therapeutics
Title of your Abstract : EFFECTS OF CLOFIBRATE ON OUABAIN-INDUCED ARRHYTHMIA IN ISOLATED RAT ATRIA
country : Geneva, Switzerland
From : Wednesday, August 28, 2013
To : Saturday, August 31, 2013
Abstract(Please copy/paste the abstract send to the congress) : Effects of clofibrate on ouabain-induced arrhythmia in isolated rat atria
Azam Bakhtiarian, Somayeh Moradi, Vahid Nikoui, Farahnaz Jazayeri
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran


Introduction: Cardiac arrhythmia is one of the critical health conditions. Clofibrate is a peroxisome proliferated-activator receptor-α (PPAR-α) agonist that is widely used for reducing triglycerides in hyperlipidemic patients. As this drug has showed several beneficial effects in relief of some cardiovascular diseases, the aim of the present study was to evaluate anti-arrhythmic effects of clofibrate on ouabain-induced arrhythmia in rats.
Materials and methods: Twenty male rats weighing 220–250 grams divided into two equal groups randomly. Group one (treatment) received clofibrate (300 mg/kg) solved in olive oil (1 ml/kg) once daily for 14 days intraperitoneally. Group two (vehicle control) only received olive oil (1 ml/kg) once daily for 14 days intraperitoneally. After induction of anesthesia, heart was rapidly removed and the atria were immersed in a tissue bath containing modified Krebs solution andattached to isometric force transducer of PowerLab machine. Time of onset of arrhythmia and asystole, atrial beating rate and contractile force were recorded and analyzed statistically with paired and student`s t-test in treatment and control groups.
Results: Clofibrate significantly postponed time of onset of arrhythmia (23.57±4.69 minutes) rather than control group (2.04±0.27 minutes, P=0.024). A significant increase in the onset time of asystole in treatment group (66.19±12.33 minutes) was observed, while this time for control group was 22.77±7.17 (P=0.004). Incubation of ouabain increased the atrial beating rate in control group significantly (P=0.022), while it does not show such effect in treatment group (P=0.845).Incubation of ouabain had no effects on contractile force in control and treatment groups (P=0.063 and P=0.539 respectively).
Conclusion: Based on the findings, clofibrate may possess potentials to reduce some kinds of cardiac arrhythmias. Further studies especially on in vivo arrhythmial models can more elucidate these beneficial effects of this drug. 
Keywords of your Abstract : clofibrate; arrhythmia; cardiovascular; PPAR; atria; rat
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/8276/Forms/306/EACPT acceptance Fri_1.docx
The presentation : Poster
The Cover of Abstract book :
Published abstract in the abstract book with the related code :
Where has your abstract been indexed? : Pubmed
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : 300
Delegates from which countries presented in the congress? : Uk, all European countries, Canada, ...
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : ASPET
What were the responses to your talking points? Were specific questions or concerns raised? : There were specific comments by the editor of Journal of clinical Pharmacology regarding my work. The specific question that was raised regarding this poster presentation was the fact that how this antihyperlipidemic drug clofibrate has antiarrhythmic effect and I discussed the important pathways that this drug might affect and more work needed to clarify this point.
If you met staff members, please list their full names & positions. : No
Please inform us if there are any follow up actions we need to talk with the members of the congress : Since My work was not presented orally therefore any comments needed when the people came to my poster presentation , I tried to answer their questions. They commented that my work can be done in vivo and after looking at the molecular level we could have better results and could publish it with European journals . “Based on the findings, clofibrate may possess potentials to reduce some kinds of cardiac arrhythmias. Further studies especially on in vivo arrhythmial models can more elucidate these beneficial effects of this drug.”
Your experiences about the travel processes(Providing ticket, accommodation,...) : Because of Iran Air delay, we missed our flight to Geneva.
Please give a briefing of your own observations and outcomes of the congress: : It was a great pleasure for me to attend the the 11th Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT) in Geneva. This congress was under the auspices of the Swiss Society of Clinical Pharmacology and Toxicology and the other sponsors, the Congress took place from 28 to 31 August 2013 at the International Conference Center Geneva (CICG), in the smallest of the world class metropolis. Clinical pharmacology provides a wide array of services, from excellence in patient care, teaching and clinical research to high standard efficient contribution in drug development and professional services in regulatory bodies. The Conference was a unique opportunity to meet top ranking specialists of various professional backgrounds involved in drug discovery, drug development, pharmacology and pharmacotherapy teaching, drug use, drug epidemiology, and drug safety.
This meeting was a good clinical Pharmacolgy congress and it was well organized.